CNBC September 27, 2023
Key Points
– AstraZeneca, Bristol Myers Squibb and Boehringer Ingelheim told CNBC they will agree to participate in the first round of Medicare drug price negotiations.
– All three pharmaceutical companies have sued to halt the process.
– AstraZeneca’s Type 2 diabetes drug Farxiga, Boehringer Ingelheim’s own diabetes drug Jardiance and Bristol Myers Squibb’s blood thinner Eliquis are among the first 10 drugs selected for price talks with Medicare.
AstraZeneca, Bristol Myers Squibb and Boehringer Ingelheim on Wednesday told CNBC they will agree to participate in the first round of Medicare drug price negotiations, even after all three pharmaceutical companies sued to halt the process last month.
AstraZeneca’s Type 2 diabetes drug Farxiga, Boehringer Ingelheim’s own diabetes drug Jardiance and...
Today's Sponsors
Today's Sponsor